Immatics NV IMTX

$7.59 -0.85 (-10.07%)

Valuation

Market cap
1,153,664,000
Revenue TTM
$54,610,000
Net income TTM
$-222,260,000
PE ratio
0.00
Forward PE
—
Profit margin
-407.00%
Debt to equity
0.00

Trading

Volume
1,256,900
Avg volume
651,152
Day's range
$7.40 – $8.57
Shares out
136,690,000
Stochastic %K
11%
Beta
1.36
Analysts
Strong Sell
Price target
$17.60

Price

Company profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipel...

Show more

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Industry
Biotechnology
Sector
Healthcare
Phone
49 7071 5397 0
Website
https://www.immatics.com
Address
Paul-Ehrlich-Strasse 15-19, Tübingen, Germany

Latest news

Stocktwits

NJgolfer Oct 3, 7:53 PM
$IMTX Perceptive is one of the best biotech funds around. Glad to see they bought into the last share offering. 2027 should be a home run for $IMTX
0 replies
RemitTekram Sep 29, 1:12 PM
$IMTX I'm going to wake you up today. This is going places based on IOVA's demand and success.
1 replies
None_ Sep 10, 10:19 PM
$IMTX
0 replies
Invescent Aug 27, 8:07 PM
$IMTX Upcoming catalysts: Oct. 19 — ESMO abstracts released Oct. 23–27 — Updated PRAME clinical data at ESMO, including IMA203CD8 + IMA402 H1 2027 — SUPRAME Phase 3 topline PFS data expected
0 replies
Invescent Aug 27, 8:05 PM
$IMTX 👀 Perceptive Life Sciences disclosed the purchase of 863,060 shares at $8.69, roughly $7.5M, as part of the recent offering. Perceptive now reports a 7.6% beneficial stake. IMTX also has multiple PRAME clinical datasets expected at ESMO in October. Institutional participation + upcoming catalysts. One to watch.
0 replies
FilingTracker Aug 27, 8:01 PM
$IMTX $7.5 million insider purchase: https://filingtracker.ai/filing/1164426/0001193125-26-371237?doc=ownership.xml
0 replies
elmono Aug 25, 4:51 PM
$IMTX predatory shorting algos. I hate market makers scamming retail
0 replies
severeblast Aug 25, 2:11 PM
$IMTX Offering are often good..Stocks are not Science where this happens than that does...
0 replies